FDA Approves ILUMYA for Adults With Active Psoriatic Arthritis

The US Food and Drug Administration has approved Sun Pharmaceutical Industries Limited’s supplemental Biologics License Application for ILUMYA, tildrakizumab-asmn, for adults with active psoriatic arthritis, according to Themachinemaker.

Themachinemaker reported that the action expands the use of ILUMYA. The publication identifies ILUMYA as an interleukin-23 inhibitor and notes that the FDA approved the product in 2018.

Supplemental application approved

Sun Pharma received FDA approval for a supplemental Biologics License Application covering ILUMYA in adults with active psoriatic arthritis, Themachinemaker reported. The approved indication adds active psoriatic arthritis to the product’s FDA history.

The reported regulatory event concerns ILUMYA, also known as tildrakizumab-asmn. Themachinemaker characterized the product as an interleukin-23 inhibitor.

Key details for sales conversations

For pharmaceutical and biotech sales professionals, the update is centered on the FDA’s approval of Sun Pharma’s supplemental application. Discussions about the news can distinguish the product’s earlier FDA approval from the newly reported use in adults with active psoriatic arthritis.

• The FDA approved Sun Pharma’s supplemental Biologics License Application.
• The approval applies to adults with active psoriatic arthritis.
• ILUMYA is tildrakizumab-asmn.
• Themachinemaker identifies ILUMYA as an interleukin-23 inhibitor.
• The product was previously approved by the FDA in 2018, according to Themachinemaker.

Reported scope of the decision

Themachinemaker described the decision as an expansion of ILUMYA’s use. Its report did not provide additional details on labeling, dosing, clinical data, or product availability.

Sales professionals discussing the event can keep communications focused on the reported FDA action: Sun Pharma’s supplemental application for ILUMYA was approved for adults with active psoriatic arthritis.